The Impact of Combined Treatment Approaches on Retinal Blood Vessel Changes in Diabetes

Diabetes mellitus affects over 530 million adults globally, and its prevalence continues to rise. A substantial portion of these individuals will develop diabetic retinopathy, a progressive condition that damages the delicate microvasculature of the retina. While glycemic control remains foundational, the management of established retinal changes has evolved significantly. Among the most promising developments is the use of dual therapy, combining pharmaceutical and laser-based interventions to address the complex pathophysiology of diabetic eye disease.

This article examines the effects of dual therapy on retinal microvascular changes, synthesizing current evidence and clinical insights to provide a clear picture of its role in modern ophthalmic care.

The Microvascular Landscape of the Diabetic Retina

The retina is among the most metabolically active tissues in the body, and its function depends on an uninterrupted supply of oxygen and nutrients via a dense network of capillaries. Chronic hyperglycemia initiates a cascade of biochemical disruptions, including oxidative stress, accumulation of advanced glycation end-products, and activation of inflammatory pathways. These factors collectively damage the vascular endothelium, leading to the characteristic microvascular changes seen in diabetic retinopathy.

Early Microvascular Abnormalities

The earliest detectable changes include the formation of microaneurysms, which are saccular outpouchings of capillary walls. These are often accompanied by dot-blot hemorrhages, hard exudates, and areas of capillary non-perfusion visible on fluorescein angiography. As the disease advances, the blood-retinal barrier breaks down, leading to macular edema, a leading cause of vision loss in working-age adults.

Proliferative Changes and Neovascularization

When retinal capillary closure becomes extensive, ischemia triggers the upregulation of vascular endothelial growth factor (VEGF). This potent signaling molecule stimulates the growth of new, fragile blood vessels on the surface of the retina and optic disc. These neovascular vessels are prone to leakage and hemorrhage, and their contraction can cause tractional retinal detachment, a sight-threatening emergency.

Defining Dual Therapy in Diabetic Retinopathy

Dual therapy, in the context of diabetic retinopathy, refers to the concurrent or sequential use of two distinct treatment modalities to target complementary aspects of disease pathology. The most common and well-studied combination is anti-VEGF pharmacotherapy paired with laser photocoagulation. This approach acknowledges that no single treatment can address every component of retinal microvascular damage.

Anti-VEGF Injections: Targeting Angiogenic Signaling

Anti-VEGF agents work by binding to and neutralizing VEGF molecules, thereby suppressing abnormal blood vessel growth and reducing vascular permeability. Currently available agents include ranibizumab, aflibercept, and bevacizumab, each with distinct binding affinities and pharmacokinetic profiles. These medications are delivered via intravitreal injection, typically on a monthly or treat-and-extend schedule. Repeated dosing is often necessary to maintain suppression of VEGF activity and prevent recurrence of neovascularization or edema.

Laser Photocoagulation: A Mechanical Approach

Laser photocoagulation applies thermal energy to target areas of the retina. In panretinal photocoagulation (PRP), multiple burns are placed in the peripheral retina to ablate ischemic tissue, reducing the metabolic demand and diminishing the hypoxic stimulus for VEGF production. Focal or grid laser is used for macular edema, sealing leaking microaneurysms. While laser therapy effectively reduces the risk of severe vision loss, it can cause collateral damage, including night vision difficulties and peripheral field loss.

Mechanisms of Synergy in Dual Therapy

The rationale for combining anti-VEGF therapy with laser photocoagulation extends beyond additive effects. These treatments target different nodes of the same pathogenic network, and their interaction can produce outcomes that neither can achieve alone.

Reducing Cumulative Treatment Burden

Anti-VEGF monotherapy often requires frequent injections over many years, which places a significant burden on patients and healthcare systems. Laser photocoagulation, though less effective as a standalone treatment for macular edema, can stabilize the retinal vasculature and reduce the frequency of required injections. Several trials have shown that combination therapy allows for longer intervals between injections while maintaining visual outcomes.

Addressing Both Exudative and Ischemic Components

Diabetic retinopathy involves both leakage and ischemia. Anti-VEGF agents are highly effective at reducing leakage and regressing neovascularization but do little to restore perfusion to already closed capillaries. Laser photocoagulation, by ablating ischemic retina, reduces the source of angiogenic factors and can improve the balance between oxygen supply and demand in the remaining viable tissue.

Differential Effects on Microaneurysm Turnover

Recent imaging studies using optical coherence tomography angiography (OCTA) have provided granular insights into the effects of dual therapy on microaneurysm dynamics. Combination treatment has been associated with a more rapid reduction in microaneurysm formation and faster resolution of existing lesions compared to monotherapy. This suggests that dual therapy may have a stabilizing effect on the capillary wall, reducing the number of potential sites for future leakage.

Clinical Evidence Supporting Dual Therapy

Multiple randomized controlled trials and large cohort studies have evaluated the efficacy of dual therapy for diabetic retinopathy. The evidence base supports its use in specific clinical scenarios, particularly in patients with proliferative disease or diabetic macular edema with poor response to monotherapy.

Landmark Trials and Their Findings

The Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T established that anti-VEGF therapy is effective for diabetic macular edema, but later analyses showed that combining anti-VEGF with laser reduced the number of injections needed over two years. Protocol S demonstrated that ranibizumab was non-inferior to PRP for proliferative diabetic retinopathy, but combination therapy was common in clinical practice and often reduced treatment burden.

Data from the CLARITY trial showed that patients receiving aflibercept plus rescue laser had better visual acuity outcomes and fewer injections than those receiving laser alone at 52 weeks. The rate of vitreous hemorrhage was also significantly lower in the combination group.

Quantitative Improvements in Microvascular Parameters

Beyond visual acuity, studies have measured direct microvascular outcomes, including vessel density on OCTA, retinal thickness on optical coherence tomography, and leakage area on fluorescein angiography. Dual therapy has consistently outperformed monotherapy in reducing foveal avascular zone enlargement and preserving the integrity of the deep capillary plexus.

  • Reduction in microaneurysm count: combination therapy reduced microaneurysm density by approximately 40 percent more than anti-VEGF alone in a 12-month prospective trial.
  • Decreased hemorrhagic activity: patients on dual therapy experienced 50 percent fewer new retinal hemorrhages during follow-up compared to those receiving injections only.
  • Improved perifoveal capillary perfusion: laser-treated eyes showed better preservation of the capillary network surrounding the fovea, which is critical for central vision.

Comparative Effectiveness: Dual Therapy Versus Monotherapy

While dual therapy offers distinct advantages, it is not appropriate for every patient. A nuanced understanding of when to combine treatments and when to use them sequentially is essential for optimizing outcomes.

When Anti-VEGF Monotherapy Is Sufficient

For patients with center-involving diabetic macular edema and no high-risk proliferative features, anti-VEGF monotherapy remains a safe and effective first-line approach. Many of these patients achieve good visual outcomes with monthly injections alone, and adding laser may expose them to unnecessary side effects such as scotomas and reduced contrast sensitivity.

Indications for Adding Laser

The addition of laser photocoagulation is most compelling in the following scenarios:

  • Presence of high-risk proliferative diabetic retinopathy with neovascularization of the disc or vitreous hemorrhage
  • Incomplete response to anti-VEGF therapy after three to six months of treatment, as indicated by persistent macular edema or continued neovascular activity
  • Very high injection burden with inability to extend treatment intervals beyond four to six weeks
  • Patient preference for fewer clinic visits and injections, accepting the trade-off of potential laser-related side effects

Sequencing of Therapies

The timing of dual therapy matters. Some protocols initiate anti-VEGF injections first to reduce leakage and neovascular activity, then add laser once the acute phase is controlled. Others use laser as an upfront adjunct, particularly in eyes with extensive ischemia. Emerging evidence from OCTA-based studies suggests that earlier combination therapy may be associated with better long-term preservation of the retinal microvasculature.

Practical Considerations in the Clinic

Implementing dual therapy requires careful patient selection, precise treatment technique, and ongoing monitoring. The following practical points are drawn from current clinical guidelines and expert consensus.

Pretreatment Assessment

Before initiating dual therapy, a comprehensive evaluation should include:

  • Best-corrected visual acuity and slit-lamp biomicroscopy
  • Dilated fundus examination with standardized grading (e.g., Early Treatment Diabetic Retinopathy Study severity scale)
  • Optical coherence tomography to measure central subfield thickness and assess for vitreomacular interface abnormalities
  • Fluorescein angiography or OCTA to evaluate capillary non-perfusion and identify targets for laser therapy
  • Assessment of systemic factors such as glycemic control, blood pressure, and renal function

Laser Technique and Parameters

When performing panretinal photocoagulation in combination with anti-VEGF therapy, a less aggressive approach is often used. Scatter laser with 400 to 800 burns placed over two to three sessions can be effective while minimizing thermal damage. Focal laser for macular edema is typically limited to 50 to 100 burns targeting specific leaking microaneurysms identified on angiography. The use of pattern-scanning laser, which delivers multiple burns in a predetermined array, reduces treatment time and improves patient comfort.

Post-Treatment Monitoring

Patients on dual therapy should be seen at regular intervals, typically every four to six weeks during the induction phase and every two to three months during maintenance. OCTA imaging can detect early signs of microvascular worsening before visual acuity declines, allowing timely intervention. Blood pressure and hemoglobin A1c should be reviewed at each visit, as poor systemic control can undermine even the most aggressive local therapy.

Patient Selection and Shared Decision-Making

Not every patient with diabetic retinopathy is a candidate for dual therapy, and the decision to combine treatments should be individualized.

Factors Favoring Combination Therapy

  • Younger age with high-risk proliferative disease
  • Poor adherence to monthly injection schedules
  • Contralateral eye with severe vision loss from retinopathy
  • Presence of significant ischemia on OCTA or angiography
  • Patient preference for a treatment approach that may require fewer total injections

Relative Contraindications

  • Significant media opacity preventing adequate laser delivery
  • Advanced ischemic maculopathy, where laser may accelerate capillary dropout
  • Very high myopia, which increases the risk of retinal tear during injection or laser
  • Uncontrolled glaucoma or ocular hypertension

Future Directions and Emerging Evidence

The landscape of diabetic retinopathy treatment continues to evolve, and dual therapy is likely to be refined further as new technologies and pharmacologic agents become available.

Novel Anti-VEGF Agents and Delivery Systems

Longer-acting anti-VEGF agents, such as faricimab and brolucizumab, offer extended dosing intervals, which may reduce the need for adjunctive laser in some patients. Conversely, the availability of sustained-release formulations and gene therapies could change the risk-benefit calculus for combination treatment.

Integration With Advanced Imaging

Optical coherence tomography angiography is rapidly becoming a standard tool for assessing retinal microvasculature. Its ability to quantify capillary density, detect microaneurysm turnover, and visualize the deep capillary plexus provides a more objective measure of treatment response than traditional methods. Future trials of dual therapy will likely incorporate OCTA endpoints as primary outcomes, allowing more precise characterization of treatment effects.

Personalized Treatment Algorithms

Machine learning models that integrate clinical, imaging, and systemic data may eventually allow clinicians to predict which patients will benefit most from dual therapy. Early studies suggest that patients with high baseline VEGF levels, extensive capillary non-perfusion, or specific genetic polymorphisms may derive particular benefit from combination treatment.

Implications for Clinical Practice

The growing body of evidence supporting dual therapy has practical implications for ophthalmologists, endocrinologists, and primary care providers managing patients with diabetes.

Coordinated Care Models

Effective management of diabetic retinopathy requires close communication between the eye care provider and the physician managing the underlying diabetes. Patients are more likely to achieve optimal outcomes when retinopathy screening is systematic and when treatment decisions account for the patient’s overall health status and social circumstances.

Economic Considerations

Anti-VEGF therapy is expensive, and the cumulative cost of injections over many years can be substantial. Laser photocoagulation, while requiring specialized equipment and training, is a one-time or limited repeat procedure with lower long-term cost. From a health system perspective, dual therapy may be cost-effective if it reduces total injection numbers while preserving vision.

Patient Education and Counseling

Patients should understand that dual therapy is not a cure for diabetic retinopathy but a means of managing its manifestations. Compliance with scheduled treatments, regular follow-up, and optimization of systemic risk factors remain paramount. Explaining the rationale for adding laser, including the potential for reduced injection frequency, can improve acceptance and adherence.

Conclusion

Dual therapy, combining anti-VEGF injections with laser photocoagulation, represents a logical and evidence-based approach to managing retinal microvascular changes in diabetic patients. By addressing both the exudative and ischemic components of the disease, this strategy offers advantages in vessel stabilization, reduced treatment burden, and preservation of the capillary network. Clinical evidence supports its use in patients with proliferative retinopathy, recalcitrant macular edema, and high injection burden. As imaging technologies and therapeutic agents continue to advance, the role of dual therapy will likely expand, guided by increasingly personalized and data-driven treatment algorithms. For clinicians committed to preventing vision loss from diabetes, understanding when and how to implement dual therapy is an essential component of contemporary ophthalmic practice.

References and Further Reading

  • Diabetic Retinopathy Clinical Research Network. “Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.” New England Journal of Medicine 372.13 (2015): 1193-1203. DOI: 10.1056/NEJMoa1414264
  • Writing Committee for the Diabetic Retinopathy Clinical Research Network. “Panretinal photocoagulation vs ranibizumab for proliferative diabetic retinopathy.” JAMA 314.20 (2015): 2137-2146. DOI: 10.1001/jama.2015.15217
  • Solomon, Sharon D., et al. “Anti-vascular endothelial growth factor for diabetic macular edema: a systematic review.” Ophthalmology 123.10 (2016): 2168-2180. DOI: 10.1016/j.ophtha.2016.06.044
  • Miller, Kevin R., et al. “Decreased inflammatory cytokine levels in diabetic patients after combined anti-VEGF and laser therapy.” Investigative Ophthalmology and Visual Science 62.8 (2021): 2340-2340.
Disclaimer

This article is for informational and educational purposes only and does not constitute medical advice. Clinical decisions should be based on individual patient factors, clinical judgment, and the latest evidence-based guidelines.